YD Bio (NASDAQ:YDES) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of YD Bio (NASDAQ:YDES) to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

YD Bio Stock Up 20.1%

Shares of NASDAQ:YDES opened at $5.73 on Friday. YD Bio has a 12 month low of $1.70 and a 12 month high of $22.00. The company has a 50-day moving average price of $3.32 and a 200 day moving average price of $4.19.

YD Bio (NASDAQ:YDES) last issued its quarterly earnings data on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share for the quarter. The company had revenue of $0.42 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its position in YD Bio stock. Cypress Capital Management LLC WY raised its position in shares of YD Bio Limited (NASDAQ:YDES) by 9.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,690 shares of the biotechnology company’s stock after acquiring an additional 3,000 shares during the period. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 as of its most recent filing with the Securities & Exchange Commission.

YD Bio Company Profile

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.